Skip to content

Influence of alcohol consumption on the volume-effect relationship of Ciprofol when combined with alfentanil for painless gastroscopy procedures

Influence of alcohol consumption on the volume-effect relationship of Ciprofol when combined with alfentanil for painless gastroscopy procedures

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083846
Enrollment
Unknown
Registered
2024-05-06
Start date
2024-05-06
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless gastroscopy

Interventions

Normal group:Each group of patients was tested separately using the Dixon sequential method, with the initial dose of cyclobutrazol set at 0.4 mg/kg and a dose gradient of 0.04 mg/kg. The presence of
conversely, the dose of the next patient was decreased by 0.04 mg/kg. If the modified alertness/sedation score was still >1 after 3 min of injection of cyclobutrazol, it was directly judged as ineffec
drinking group:Each group of patients was tested separately using the Dixon sequential method, with the initial dose of cyclobutrazol set at 0.4 mg/kg and a dose gradient of 0.04 mg/kg. The presence o

Sponsors

Baoding NO.1 Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Male patients who to undergo elective painless gastroscopy; 2. Age< 65 years old; 3BMI <28kg\/m2; 4. ASAI. or Class II; 5. Mouth opening=2.5cm;6. Normal range of motion of head and neck; 7. Mallampati Class I or II; 8. No history of alcohol consumption within 24 hours; 9. The patient has fully understood the nature of the study, voluntarily participated in this trial and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Neuromuscular junction disease; 2. History of allergy to the test drug; 3. History of neurological diseases; 4. High risk of inhalation; 5. Expected airway difficulties; 6. Use sedatives; 7. Alcoholics, daily alcohol consumption greater than 100g and alcohol withdrawal symptoms (tremor, agitation, disorientation dysfunction) or acute alcohol poisoning; 8. Severe smokers; 9. For any reason, the investigators believe that there are any circumstances that are not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
median effective dose;

Secondary

MeasureTime frame
SpO2, HR and MAP were recorded before anesthesia (T0), 1min after injection (T1) and gastroscopy (T2);Adverse effects such as bradycardia, hypotension, hypoxia, choking, body movement, and swallowing during the induction period;

Countries

China

Contacts

Public ContactChunguang Wang

Baoding NO.1 Central Hospital

13831253611@163.com+86 186 1778 9771

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026